Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: HLS Therapeutics Inc.

Market Cap 97.67M 84.18M 77.47M 72.68M 137M 9.23B 138M 916M 358M 4.52B 367M 359M 15.64B P/E Ratio 2026 *
-15.6x
P/E Ratio 2027 * -104x
Enterprise Value 97.67M 84.18M 77.47M 72.68M 137M 9.23B 138M 916M 358M 4.52B 367M 359M 15.64B EV / Sales 2026 *
1.68x
EV / Sales 2027 * 1.52x
Free-Float
99.48%
Yield 2026 *
-
Yield 2027 * -
1 day-3.37%
Current month-3.37%
1 month-7.95%
3 months-6.31%
6 months-7.89%
Current year-8.16%
1 month 3.15
Extreme 3.15
3.36
Current year 3
Extreme 3
3.44
1 year 3
Extreme 3
4.02
3 years 2.22
Extreme 2.22
4.95
5 years 2.22
Extreme 2.22
16.44
10 years 0
Extreme 0
19.1
Manager TitleAgeSince
Chief Executive Officer 58 01/05/2023
Director of Finance/CFO 61 26/01/2024
Compliance Officer 45 07/05/2018
Director TitleAgeSince
Chairman 48 22/06/2023
Director/Board Member 61 22/06/2023
Director/Board Member 58 01/05/2023
Change 5-day change 1-year change 3-year change Capi.($)
-3.37%0.00% - - 97.67M
-0.52%+1.17%+7.79%+93.87% 91.79B
+0.86%+10.39%+38.99%+153.17% 52.43B
+6.06%-4.11%-13.85%+229.41% 21.42B
-0.37%+0.12%-11.28%-26.90% 8.13B
-0.38%+2.04%-34.90%-30.42% 7.54B
-0.41%-1.63%-11.82%-36.59% 6.77B
-1.05%+0.05%+12.43%+18.47% 6.49B
-1.00%+0.06%-2.55%+17.62% 5.32B
+1.67%-2.01%-10.48%-14.79% 3.53B
Average +0.16%+0.54%-2.85%+44.87% 22.6B
Weighted average by Cap. +0.46%+1.88%+10.12%+103.37%

Financials

2026 *2027 *
Net sales 58.03M 50.02M 46.03M 43.18M 81.12M 5.48B 81.93M 544M 213M 2.69B 218M 213M 9.29B 64.31M 55.43M 51.02M 47.86M 89.9M 6.08B 90.8M 603M 236M 2.98B 241M 236M 10.3B
Net income -6.26M -5.4M -4.97M -4.66M -8.76M -592M -8.84M -58.75M -22.95M -290M -23.51M -23.01M -1B -1.05M -905K -833K -781K -1.47M -99.23M -1.48M -9.85M -3.85M -48.6M -3.94M -3.86M -168M
Net Debt - -
Logo HLS Therapeutics Inc.
HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules are a single-molecule prescription product for the treatment of cardiovascular disease.
Employees
85
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
3.123USD
Average target price
5.179USD
Spread / Average Target
+65.84%

Quarterly revenue - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!